A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)

被引：0
|
作者：
Dizman, Nazli
Adra, Nabil
Vaishampayan, Ulka N.
Xiao, Lianchun
Yuan, Ying
Campbell, Matthew T.
Gao, Jianjun
Zurita, Amado J.
Jonasch, Eric
Tannir, Nizar M.
Shah, Amishi Yogesh
Msaouel, Pavlos
Hahn, Andrew Warren
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
[3] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4542
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
    Karam, Jose A.
    Msaouel, Pavlos
    Haymaker, Cara L.
    Matin, Surena F.
    Campbell, Matthew T.
    Zurita, Amado J.
    Shah, Amishi Y.
    Wistuba, Ignacio I.
    Marmonti, Enrica
    Duose, Dzifa Y.
    Parra, Edwin R.
    Soto, Luisa Maren Solis
    Laberiano-Fernandez, Caddie
    Lozano, Marisa
    Abraham, Alice
    Hallin, Max
    Chin, Curtis D.
    Olson, Peter
    Der-Torossian, Hirak
    Yan, Xiaohong
    Tannir, Nizar M.
    Wood, Christopher G.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [2] Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
    Jose A. Karam
    Pavlos Msaouel
    Cara L. Haymaker
    Surena F. Matin
    Matthew T. Campbell
    Amado J. Zurita
    Amishi Y. Shah
    Ignacio I. Wistuba
    Enrica Marmonti
    Dzifa Y. Duose
    Edwin R. Parra
    Luisa Maren Solis Soto
    Caddie Laberiano-Fernandez
    Marisa Lozano
    Alice Abraham
    Max Hallin
    Curtis D. Chin
    Peter Olson
    Hirak Der-Torossian
    Xiaohong Yan
    Nizar M. Tannir
    Christopher G. Wood
    Nature Communications, 14
  • [3] Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial
    Msaouel, Pavlos
    Yu, Kai
    Yuan, Ying
    Chen, Jianfeng
    Yan, Xinmiao
    Karki, Menuka
    Duan, Fei
    Sheth, Rahul A.
    Rao, Priya
    Sircar, Kanishka
    Shah, Amishi Y.
    Zurita, Amado J.
    Genovese, Giannicola
    Li, Min
    Yeh, Chih-Chen
    Dang, Minghao
    Han, Guangchun
    Chu, Yanshuo
    Hallin, Max
    Olson, Peter
    Yang, Rui
    Slavin, Daniela
    Der-Torossian, Hirak
    Chin, Curtis D.
    Tannir, Nizar M.
    Wang, Linghua
    Gao, Jianjun
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [4] Phase II study of sitravatinib in combination with nivolumab in patients undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (ccRCC).
    Karam, Jose A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study
    Al-Danakh, Abdullah
    Safi, Mohammed
    Alradhi, Mohammed
    Chen, Qiwei
    Baldi, Salem
    Zhu, Xinqing
    Yang, Deyong
    CELLS, 2022, 11 (22)
  • [6] A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy.
    Msaouel, Pavlos
    Thall, Peter F.
    Yuan, Ying
    Chen, Isan
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [7] Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
    Gebrael, Georges
    Jo, Yeonjung
    Thomas, Vinay Mathew
    Li, Haoran
    Sayegh, Nicolas
    Tripathi, Nishita
    Srivastava, Ayana
    Nordblad, Blake
    Dal, Emre
    Narang, Arshit
    Brundage, James
    Campbell, Patrick
    Fortuna, Gliceida Galarza
    Chehade, Chadi Hage
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    CANCER, 2024, 130 (15) : 2621 - 2628
  • [8] Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Hsieh, James J.
    Rao, Arpit
    Pinto, Alvaro
    Bilen, Mehmet Asim
    Cohn, Allen Lee
    Di Simone, Christopher
    Shaffer, David R.
    Sarrio, Regina Girones
    Ribe, Sara Gunnestad
    Wu, Jane
    Schmidt, Emmett, V
    Perini, Rodolfo F.
    Kubiak, Peter
    Smith, Alan D.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
    Gul, Anita
    Stewart, Tyler F.
    Mantia, Charlene M.
    Shah, Neil J.
    Gatof, Emily Stern
    Long, Ying
    Allman, Kimberly D.
    Ornstein, Moshe C.
    Hammers, Hans J.
    McDermott, David F.
    Atkins, Michael B.
    Hurwitz, Michael
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3088 - +
  • [10] A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
    Msaouel, Pavlos
    Goswami, Sangeeta
    Thall, Peter F.
    Wang, Xuemei
    Yuan, Ying
    Jonasch, Eric
    Gao, Jianjun
    Campbell, Matthew T.
    Shah, Amishi Yogesh
    Corn, Paul Gettys
    Tam, Alda L.
    Ahrar, Kamran
    Rao, Priya
    Sircar, Kanishka
    Cohen, Lorenzo
    Basu, Sreyashi
    Duan, Fei
    Jindal, Sonali
    Zhang, Yuwei
    Chen, Hong
    Yadav, Shalini S.
    Shazer, Ronald
    Der-Torossian, Hirak
    Allison, James P.
    Sharma, Padmanee
    Tannir, Nizar M.
    SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (641)
12345